Evaluation of serum levels of chemokines during interferon beta treatment in multiple sclerosis patients

Longitudinal evaluation of serum chemokine levels in multiple sclerosis patients treated with interferon beta

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN45526724

Enrollment

Registered

2011-01-21

Start date

2006-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis Nervous System Diseases Multiple sclerosis

Interventions

Blood samples were taken 7 times each other month for one year. Clinical evaluation, EDSS score and imaging by magnetic ressonance at the initial and final evaluation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with multiple sclerosis diagnosed by McDonald criteria 2001 2. Aged between 18 and 50 years old 3. Up to ten years of disease 4. Up to 5 points on the Expanded Disability Status Scale (EDSS) 5. At least one gadolinium enhacement lesion on magnetic ressonance or one clinical relapse in the year prior to study

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Ttreatment with immunossupressor regimen 3. Stability of disease more than one year

Design outcomes

Primary

Measure	Time frame
Comparison of serum chemokines levels with patients and disease characteristics	—

Secondary

Measure	Time frame
Comparison of serum chemokines levels with lesions by magnetic resonance imaging (MRI)	—

Countries

Brazil

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 28, 2026